Keyphrases
Tumor-infiltrating Lymphocytes
100%
T Cells
54%
Chimeric Antigen Receptor T Cells (CAR-T)
50%
Adoptive Cell Therapy
50%
Metastatic Melanoma
50%
Melanoma
43%
Melanoma Cells
31%
Adoptive Cell Transfer
21%
Melanoma Patients
19%
Chimeric Antigen Receptor T-cell Therapy
16%
CEACAM1
16%
CD19 chimeric Antigen Receptor T Cells
14%
Clinical Response
14%
Adoptive Transfer
13%
Interleukin-2
12%
Cell Adhesion Molecule 1 (CADM1)
12%
Antitumor
11%
CD28
11%
Tumor
11%
Lymphocyte Culture
11%
Genetic Modification
10%
MicroRNA
10%
T Cell Activation
10%
CD19
10%
Autologous Tumors
10%
Anti-CD19 chimeric Antigen Receptor T Cells
9%
Normal Human
9%
Acute Lymphoblastic Leukemia
9%
Autoreactive T Cells
9%
Carcinoembryonic Antigen
9%
Constitutively Active
8%
Effector Function
8%
CD8+ T Cells
7%
Anti-melanoma
7%
Intercellular Adhesion molecule-1 (ICAM-1)
7%
B-cell Malignancies
7%
Relapsed or Refractory Acute Myeloid Leukemia
7%
Ipilimumab
6%
High-dose interleukin-2
6%
Complete Response
6%
Large B-cell Lymphoma
6%
ADAR1
6%
CD40
6%
Overall Survival
6%
Adoptive Immunotherapy
6%
Adenosine Deaminase Acting on RNA
6%
MRNA Electroporation
6%
Interferon-α (IFN-α)
6%
Immune Resistance
6%
Adoptive Transfer Therapy
6%
Medicine and Dentistry
Tumor Infiltrating Lymphocyte
58%
Melanoma
54%
T Cell
49%
Metastatic Melanoma
41%
Neoplasm
39%
Chimeric Antigen Receptor T-Cell
38%
Cell Therapy
35%
Immunotherapy
29%
Chimeric Antigen Receptor
20%
Interleukin 2
15%
Transfer Cell
14%
Adoptive Transfer
14%
Carcinoembryonic Antigen Related Cell Adhesion Molecule 1
13%
Melanoma Cell
12%
Acute Lymphoblastic Leukemia
12%
Chimeric Antigen Receptor T-Cell Immunotherapy
11%
Diseases
9%
Receptor
9%
Infusion
9%
T Lymphocyte
8%
Malignant Neoplasm
8%
Large-Cell Lymphoma
7%
Drug Megadose
7%
Cytotoxic T-Cell
7%
Lymphocyte
7%
Lymphocyte Culture
6%
microRNA
6%
Overall Survival
6%
Cancer
6%
Tumor Necrosis Factor
6%
Secretion (Process)
6%
Integrin
6%
B-Cell Lymphoma
6%
Messenger RNA
5%
Leukapheresis
5%
Immunology and Microbiology
T Cell
72%
Tumor-Infiltrating Lymphocytes
65%
Immunotherapy
35%
Melanoma Cell
32%
CD19
26%
Chimeric Antigen Receptor T-Cell
24%
Transfer Cell
19%
Tumor-Associated Macrophage
16%
CEACAM1
16%
Chimeric Antigen Receptor
15%
Interleukin 2
14%
B Cell
13%
Chimeric Antigen Receptor T-Cell Therapy
12%
Cell Adhesion Molecule 1
12%
Lymphocyte
11%
Secretion (Process)
10%
Cell Line
10%
CD28
9%
Carcinoembryonic Antigen
9%
Cytokine
8%
Cytotoxic T-Cell
8%
Neoantigen
8%
Tumor Necrosis Factor
7%
Natural Killer Cell
7%
Lymphocyte Culture
7%
DNA Modification
7%
Electroporation
6%
interferon
6%
Normal Human
6%
Immunocompetent Cell
6%
Overall Survival
6%
Adoptive Immunotherapy
6%
Adenosine Deaminase
6%
Ipilimumab
5%
T Cell Receptor
5%
Tumor Cell
5%
Adjuvant
5%
Downregulation
5%
Antineoplastic Activity
5%
Cytotoxicity
5%
